Compare XPEV & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPEV | GKOS |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 10.6B |
| IPO Year | 2020 | 2015 |
| Metric | XPEV | GKOS |
|---|---|---|
| Price | $11.87 | $182.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $23.08 | ★ $126.92 |
| AVG Volume (30 Days) | ★ 5.7M | 818.6K |
| Earning Date | 05-20-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | $25.76 | $23.32 |
| Revenue Next Year | $25.98 | $27.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $11.54 | $73.16 |
| 52 Week High | $28.20 | $184.00 |
| Indicator | XPEV | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 36.34 | 80.94 |
| Support Level | $11.77 | $99.75 |
| Resistance Level | $13.34 | $184.00 |
| Average True Range (ATR) | 0.31 | 7.47 |
| MACD | -0.05 | 1.53 |
| Stochastic Oscillator | 14.21 | 95.68 |
Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold about 430,000 EVs in 2025, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.